The inhibition of the NLRP1 inflammasome by Tim-4 in liver macrophages through the LKB3/AMPKα pathway serves as an intervention strategy for NAFLD progression. This evidence concerns the gene NLRP1 and metabolic dysfunction-associated steatotic liver disease.